UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Strategy Inc
MSTR
|
+$1.21B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$855M |
| 3 |
Microsoft
MSFT
|
+$810M |
| 4 |
Advanced Micro Devices
AMD
|
+$805M |
| 5 |
Boeing
BA
|
+$739M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$561M |
| 2 |
Amneal Pharmaceuticals
AMRX
|
+$169M |
| 3 |
Eli Lilly
LLY
|
+$161M |
| 4 |
Unity
U
|
+$158M |
| 5 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.49% |
| 2 | Financials | 9.06% |
| 3 | Consumer Discretionary | 7.01% |
| 4 | Healthcare | 6.25% |
| 5 | Industrials | 6.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LINE
5851
PUT
Lineage Inc
LINE
$9.65B
| $486K | ﹤0.01% |
+8,300
| New | +$564K |
|
5852
CALL
Applovin
APP
$116B
| $486K | ﹤0.01% |
+1,500
| New | +$379K |
|
5853
Erasca
ERAS
$6.39B
| $485K | ﹤0.01% |
193,168
-37,454
| -16% | -$103K |
|
5854
Pacer Lunt Large Cap Alternator ETF
ALTL
$94.4M
| $485K | ﹤0.01% |
13,043
-5,467
| -30% | -$210K |
|
5855
AnaptysBio
ANAB
$1.68B
| $485K | ﹤0.01% |
36,606
-32
| -0.1% | -$775 |
|
5856
Unity Bancorp
UNTY
$599M
| $484K | ﹤0.01% |
11,101
+5,683
| +105% | +$238K |
|
5857
Carriage Services
CSV
$569M
| $483K | ﹤0.01% |
12,125
-4,667
| -28% | -$172K |
|
5858
Cars.com
CARS
$660M
| $481K | ﹤0.01% |
27,759
+12,696
| +84% | +$222K |
|
|
OPRA
5859
Opera Ltd
OPRA
$1.79B
| $481K | ﹤0.01% |
25,383
-70,410
| -74% | -$1.26M |
|
|
HEQ
5860
John Hancock Hedged Equity & Income Fund
HEQ
$140M
| $480K | ﹤0.01% |
46,966
+10,911
| +30% | +$118K |
|
5861
Pulse Biosciences
PLSE
$3.02B
| $479K | ﹤0.01% |
27,538
+14,746
| +115% | +$260K |
|
5862
CALL
Progressive
PGR
$125B
| $479K | ﹤0.01% |
+2,000
| New | +$503K |
|
5863
State Street SPDR S&P Health Care Services ETF
XHS
$208M
| $478K | ﹤0.01% |
5,305
-552
| -9% | -$52.1K |
|
5864
The RMR Group
RMR
$332M
| $478K | ﹤0.01% |
23,165
+7,471
| +48% | +$173K |
|
|
SQEW
5865
DELISTED
LeaderShares Equity Skew ETF
SQEW
| $478K | ﹤0.01% |
14,199
+13,826
| +3,707% | +$483K |
|
5866
BioXcel Therapeutics
BTAI
$27.8M
| $478K | ﹤0.01% |
79,806
+78,979
| +9,550% | +$660K |
|
5867
Star Group
SGU
$423M
| $477K | ﹤0.01% |
41,355
-1,694
| -4% | -$19.9K |
|
5868
Bassett Furniture
BSET
$176M
| $476K | ﹤0.01% |
34,408
+32,789
| +2,025% | +$473K |
|
|
SHYF
5869
DELISTED
The Shyft Group
SHYF
| $476K | ﹤0.01% |
40,504
+21,157
| +109% | +$273K |
|
|
PPTA
5870
Perpetua Resources
PPTA
$3.09B
| $475K | ﹤0.01% |
44,561
+26,361
| +145% | +$270K |
|
5871
Puma Biotechnology
PBYI
$454M
| $474K | ﹤0.01% |
155,571
+128,477
| +474% | +$374K |
|
|
DFNS
5872
T3 Defense Inc
DFNS
$38.3M
| $473K | ﹤0.01% |
103
-145
| -58% | -$142K |
|
|
ZOM
5873
DELISTED
Zomedica Corp.
ZOM
| $472K | ﹤0.01% |
3,935,437
+3,890,909
| +8,738% | +$490K |
|
5874
Precigen
PGEN
$2.59B
| $472K | ﹤0.01% |
421,240
+321,716
| +323% | +$274K |
|
5875
LanzaTech
LNZA
$69.8M
| $471K | ﹤0.01% |
3,436
+2,471
| +256% | +$371K |
|
Similar funds
UBS Group's Q4 2024 Portfolio in Review
As of Q4 2024, UBS Group held 10,816 positions worth $541B, up 18% from $459B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
UBS Group deployed $80.6B of net new capital in Q4 2024, opening 1,382 new positions and adding to 6,044 existing holdings. Its largest new stake was Primo Brands: 1,234,826 shares worth $38M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was UnitedHealth, an estimated $561M trimmed.
- UBS Group's largest Q4 2024 buy was Primo Brands: 1,234,826 shares worth $38M.
- UBS Group added most to Strategy Inc in Q4 2024, an estimated $1.21B increase.
- UBS Group's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $561M.
- UBS Group fully exited CATALENT, INC. in Q4 2024, selling an estimated $86M.
- UBS Group's ten largest holdings make up 16% of its $541B portfolio in Q4 2024.
- UBS Group opened 1,382 new positions and closed 943 in Q4 2024.
- UBS Group's portfolio value rose 18% quarter-over-quarter to $541B.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.